/APLT
APLT Stock - Applied Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$0.13+1.13%
+$0.00 (+1.13%) • Dec 19
58
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.40
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+100.0%upside
Target: $0.25
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for APLT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.12 – $0.13
TARGET (TP)$0.25
STOP LOSS$0.12
RISK/REWARD1:25.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.00
52W High$1.50
52W Low$0.10
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $455,000 | $9.99M | N/A | N/A | N/A |
| Gross Profit | $-48,289,000 | $-43,912,000 | $-441,000 | N/A | N/A |
| Gross Margin | -10613.0% | -439.4% | N/A | N/A | N/A |
| Operating Income | $-104,299,000 | $-64,535,000 | $-82,950,000 | $-105,618,000 | $-94,466,000 |
| Net Income | $-105,624,000 | $-119,763,000 | $-82,508,000 | $-105,584,000 | $-93,961,000 |
| Net Margin | -23214.1% | -1198.5% | N/A | N/A | N/A |
| EPS | $-0.76 | $-1.42 | $-2.18 | $-4.12 | $-4.28 |
Company Overview
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
60%
Hold / Neutral
2
40%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
3 Bullish2 Neutral/Bearish
Price Targets
$6
Average Target
↑ 4860.0% Upside
Now
$1
Low
$6
Average
$12
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 12th 2025 | Robert W. Baird | Downgrade | Neutral | - |
| December 3rd 2025 | Leerink Partners | Downgrade | Market Perform | $1 |
| December 23rd 2024 | William Blair | Downgrade | Market Perform | - |
| December 2nd 2024 | UBS | Downgrade | Neutral | $2← $13 |
| November 29th 2024 | RBC Capital Mkts | Downgrade | Sector Perform | $4← $12 |
| July 31st 2024 | William Blair | Initiation | Outperform | - |
| March 26th 2024 | RBC Capital Mkts | Initiation | Outperform | $12 |
| February 22nd 2024 | Leerink Partners | Initiation | Outperform | $12 |
Earnings History & Surprises
APLTBeat Rate
56%
Last 16 quarters
Avg Surprise
-18.6%
EPS vs Estimate
Beats / Misses
9/7
Last 12 quarters
Latest EPS
$-0.13
Q4 2025
EPS Surprise History
Q1 24
-139.5%
$-0.45vs$-0.19
Q2 24
-320.2%
$-0.67vs$-0.16
Q3 24
+112.2%
$0.02vs$-0.16
Q4 24
-200.8%
$-0.48vs$-0.16
Q2 25
+272.4%
$0.32vs$-0.18
Q2 25
+17.4%
$-0.15vs$-0.18
Q3 25
+10.9%
$-0.15vs$-0.17
Q4 25
+7.5%
$-0.13vs$-0.14
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 13, 2025 | $-0.14 | $-0.13 | +7.5% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.17 | $-0.15 | +10.9% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.18 | $-0.15 | +17.4% | ✓ BEAT |
Q2 2025 | Apr 14, 2025 | $-0.18 | $0.32 | +272.4% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.16 | $-0.48 | -200.8% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.16 | $0.02 | +112.2% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.16 | $-0.67 | -320.2% | ✗ MISS |
Q1 2024 | Mar 6, 2024 | $-0.19 | $-0.45 | -139.5% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.24 | $-0.47 | -91.3% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.27 | $-0.37 | -41.0% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.31 | $-0.18 | +41.3% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-0.46 | $-0.29 | +37.3% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.48 | $-0.40 | +16.5% | ✓ BEAT |
Q3 2022 | Aug 12, 2022 | $-0.75 | $-0.96 | -27.6% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.83 | $-0.88 | -5.8% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-1.20 | $-1.04 | +13.8% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | — | $-1.09 | — | — |
Q3 2021 | Aug 12, 2021 | — | $-0.99 | — | — |
Q2 2021 | May 11, 2021 | — | $-1.00 | — | — |
Q1 2021 | Mar 18, 2021 | — | $-0.98 | — | — |
Latest News
Trading Halt: Halt status updated at 5:50:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 11, 2025, 10:50 PM
Trading Halt: Halted at 5:21:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 11, 2025, 10:21 PM
Leerink Partners Downgrades Applied Therapeutics to Market Perform, Lowers Price Target to $1
📉 NegativeBenzinga•Dec 3, 2025, 01:48 PM
Applied Therapeutics Initiates Process To Explore Strategic Alternatives, Reduces Workforce By 46%
📉 NegativeBenzinga•Nov 20, 2025, 12:09 PM
Applied Therapeutics shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Nov 13, 2025, 02:05 PM
Applied Therapeutics Q3 EPS $(0.13) Beats $(0.14) Estimate, Sales $1.000M
📈 PositiveBenzinga•Nov 13, 2025, 12:18 PM
Applied Therapeutics Meets With FDA On Potential Drug Filing For Rare Nerve Disease CMT-SORD
➖ NeutralBenzinga•Sep 29, 2025, 11:34 AM
Applied Therapeutics Reports Q2 Loss
📉 NegativeThe Motley Fool•Aug 13, 2025, 10:12 PM
Frequently Asked Questions about APLT
What is APLT's current stock price?
Applied Therapeutics, Inc. (APLT) is currently trading at $0.13 per share. The stock has moved +1.13% today.
What is the analyst price target for APLT?
The average analyst price target for APLT is $0.25, based on 1 analyst.
What sector is Applied Therapeutics, Inc. in?
Applied Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is APLT's market cap?
Applied Therapeutics, Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does APLT pay dividends?
No, Applied Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCRBP
Corbus Pharmaceuticals Holdings, Inc.
$8.12
Mkt Cap: $0.1B
CRDF
Cardiff Oncology, Inc.
$2.57
Mkt Cap: $0.2B
ELTX
Elicio Therapeutics, Inc.
$7.94
Mkt Cap: $0.1B
FBRX
Forte Biosciences, Inc.
$29.69
Mkt Cap: $0.4B
MIST
Milestone Pharmaceuticals Inc.
$2.15
Mkt Cap: $0.2B
MOLN
Molecular Partners AG
$4.39
Mkt Cap: $0.2B
NKTX
Nkarta, Inc.
$1.79
Mkt Cap: $0.1B
PEPG
PepGen Inc.
$5.42
Mkt Cap: $0.4B
RANI
Rani Therapeutics Holdings, Inc.
$1.51
Mkt Cap: $0.1B
SAVA
Cassava Sciences, Inc.
$2.17
Mkt Cap: $0.1B
Explore stocks similar to APLT for comparison